Psyence Signs Letter of Intent with Australian CRO iNGENū
January 08, 2023 19:00 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
December 15, 2022 08:47 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and...
Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor
December 14, 2022 09:00 ET
|
Psyence Group Inc.
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
GOODMIND™ Available for Sale in the United Kingdom and Europe - Exclusive Distribution Agreement Concluded With This Works
November 29, 2022 09:37 ET
|
Psyence Group Inc.
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural...
Psyence Group Announces Strategic Private Placement
November 10, 2022 07:00 ET
|
Psyence Group Inc.
TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Completes Export of Psilocybin Mushrooms to Portugal
September 29, 2022 07:00 ET
|
Psyence Group Inc.
TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has successfully exported medical grade...
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
September 22, 2022 07:00 ET
|
Psyence Group Inc.
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in...
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
September 19, 2022 07:00 ET
|
Psyence Group Inc.
TORONTO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
September 07, 2022 11:00 ET
|
Psyence Group Inc.
TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
Psyence Group Corporate Update
June 02, 2022 07:00 ET
|
Psyence Group Inc.
Highlights: Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament HealthDr. Clive Ward-Able has been...